Membrane transporter proteins: A challenge for CNS drug development

Dialogues in Clinical Neuroscience

Volumn 8, Issue 3, 2006, Pages 311-321

  Girardin, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

ATP binding cassette transporter; Blood brain barrier; Drug distribution; Drug transporter; Solute linked carrier

Indexed keywords

ABC TRANSPORTER; AMFEBUTAMONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CATION TRANSPORT PROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; CITALOPRAM; CLARITHROMYCIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPROTEIN P; LOPERAMIDE; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NEUROTRANSMITTER; PAROXETINE; PENICILLIN G; PROBENECID; PROTEIN SOLUTE LINKED CARRIER; QUINIDINE; RISPERIDONE; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE; VERAPAMIL;

APICAL MEMBRANE; BASOLATERAL MEMBRANE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN CAPILLARY; BRAIN VENTRICLE; CATION TRANSPORT; CENTRAL NERVOUS SYSTEM; CHOROID PLEXUS; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; ENDOTHELIUM CELL; FENESTRATION; HUMAN; ION TRANSPORT; MEMBRANE TRANSPORT; MOTHER FETUS RELATIONSHIP; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TIGHT JUNCTION; TISSUE DISTRIBUTION;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DESIGN; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACOLOGY; POLYMORPHISM, GENETIC;

EID: 33750589959     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000;89:1371-1388.
2. Kullak-Ublick GA, Fisch T, Oswald M, et al. Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett. 1998;424:173-176.
3. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov Today. 2001;6:150-156.
4. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discov Today. 2001;6:206-212.
5. Vergani P, Basso C, Mense M, Nairn AC, Gadsby DC. Control of the CFTR channel's gates. Biochem Soc Trans. 2005;33(Pt 5):1003-1007.
6. Herget M, Tampe R. Intracellular peptide transporters in human - compartmentalization of the "peptidome." Pflugers Arch. 2006;May 18 [Epub ahead of print].
7. Pauli-Magnus C, Lang T, Meier Y, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics. 2004;14:91-102.
8. Fernandez-Marmiesse A, Salas A, Vega A, Fernandez-Lorenzo JR, Barreiro J, Carracedo A. Mutation spectra of ABCC8 gene in Spanish patients with hyperinsulinism of infancy (HI). Hum Mutat. 2006;27:214.
9. Gueugnon F, Volodina N, Taouil JE, et al. A novel cell model to study the function of the adrenoleukodystrophy-related protein. Biochem Biophys Res Commun. 2006;341:150-157.
10. Bekri S, Kispal G, Lange H, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood. 2000;96:3256-3264.
11. Stenirri S, Battistella S, Fermo I, et al. De novo deletion removes a conserved motif in the C-terminus of ABCA4 and results in cone-rod dystrophy. Clin Chem Lab Med. 2006;44:533-537.
12. Michaelides M, Hardcastle AJ, Hunt DM, Moore AT. Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis. Surv Ophthalmol. 2006;51:232-528.
13. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115:3285-3290.
14. Sefkova J, Poledne R, Hubacek JA. ATP-binding cassette (ABC) transporters in human metabolism and diseases. Physiol Res. 2004;53:235-243.
15. Redzic ZB, Biringer J, Barnes K, et al. Polarized distribution of nucleoside transporters in rat brain endothelial and choroid plexus epithelial cells. J Neurochem. 2005;94:1420-1426.
16. Steuer H, Jaworski A, Elger B, et al. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier. Invest Ophthalmol Vis Sci. 2005;46:1047-1053.
17. Hawkins RA, Peterson DR, Vina JR. The complementary membranes forming the blood-brain barrier. IUBMB Life. 2002;54:101-107.
18. Ganong WF. Circumventricular organs: definition and role in the regulation of endocrine and autonomic function. Clin Exp Pharmacol Physiol. 2000;27:422-427.
19. Strazielle N, Khuth ST, Ghersi-Egea JF. Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations. Adv Drug Deliv Rev. 2004;56:1717-1740.
20. Emerich DF, Vasconcellos AV, Elliott RB, Skinner SJ, Borlongan CV. The choroid plexus: function, pathology and therapeutic potential of its transplantation. Expert Opin Biol Ther. 2004;4:1191-201.
21. Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res. 2005;22:1559-1577.
22. Ghersi-Egea JF, Strazielle N. Choroid plexus transporters for drugs and other xenobiotics. J Drug Target. 2002;10:353-357.
23. Hagenbuch B, Gao B, Meier PJ. Transport of xenobiotics across the blood-brain barrier. News Physiol Sci. 2002;17:231-234.
24. Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005;76:22-76.
25. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006;234:4-33.
26. Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet. 2002;41:81-92.
27. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13:129-134.
28. Kusuhara H, Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx. 2005;2:73-85.
29. Oswald C, Holland IB, Schmitt L. The motor domains of ABC-transporters. What can structures tell us? Naunyn Schmiedebergs Arch Pharmacol. 2006;372:385-399.
30. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204:216-237.
31. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994;269:27807-27810.
32. Leier I, Jedlitschky G, Buchholz U, et al. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J. 1996;314(Pt 2):433-437.
33. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78:260-277.
34. Soontornmalai A, Vlaming ML, Fritschy JM. Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience. 2006;138:159-169.
35. Calatozzolo C, Gelati M, Ciusani E, et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol. 2005;74:113-121.
36. Bronger H, Konig J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res. 2005;65:11419-11428.
37. Kubota H, Ishihara H, Langmann T, et al. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res. 2006;68:213-228.
38. Toornvliet R, van Berckel BN, Luurtsema G, et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79:540-548.
39. Sasongko L, Link JM, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther. 2005;77:503-514.
40. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447:653-665.
41. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Introduction. Pflugers Arch. 2004;447:465-468.
42. Hagenbuch B, Meier PJ. The superfamily of organic jnion transporting polypeptides. Biochim Biophys Acta. 2003;1609:1-18.
43. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002;16:2283-2296.
44. Galic S, Schneider HP, Broer A, Deitmer JW, Broer S. The loop between helix 4 and helix 5 in the monocarboxylate transporter MCT1 is important for substrate selection and protein stability. Biochem J. 2003;376(Pt 2):413-422.
45. Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 2004;447:619-628.
46. Enerson BE, Drewes LR. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J Pharm Sci. 2003;92:1531-1544.
47. Bhattacharya I, Boje KM. GHB (gamma-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier. J Pharmacol Exp Ther. 2004;311:92-98.
48. Busch AE, Karbach U, Miska D, et al. Human neurons express the poly-specific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998;54:342-352.
49. van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ. Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001;298:110-115.
50. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
51. Choo EF, Kurnik D, Muszkat M, et al. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther. 2006;317:1012-1018.
52. Lee W, Glaeser H, Smith LH, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem. 2005;2803610-9617.
53. O'Kane DJ, Weinshilboum RM, Moyer TP. Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics. 2003;4:1-4.
54. Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev. 2003;35:417-454.
55. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42:59-98.
56. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502.
57. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43:285-307.
58. Babaoglu MO, Bayar B, Aynacioglu AS, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther. 2005;78:619-626.
59. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit. 2004;26:180-185.
60. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348:1442-1448.
61. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537.
62. Crivori P, Poggesi I. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Eur J Med Chem. 2006;Apr 24 [Epub ahead of print].
63. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:432-443.
64. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing ef avirenz and/or nelfinavir: an adult AIDS Clinical Trials Group Study. J Infect Dis. 2005;192:1931-1942.
65. Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol. 2003;58:809-812.
66. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002;2:191-196.
67. Illmer T, Schuler US, Thiede C et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62:4955-4962.
68. Yamauchi A, Ieiri I, Kataoka Y, et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002;74:571-572.
69. Sparreboom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther. 2004;76:38-44.
70. Fujita T, Brown C, Carlson EJ, et al. Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics. 2005;15:201-209.
71. Kerb R, Brinkmann U, Chatskaia N, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics. 2002;12:591-595.
72. Leabman MK, Huang CC, Kawamoto M, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002;12:395-405.
73. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev. 2006;58:140-161.
74. Elferink RO, Groen AK. Genetic defects in hepatobiliary transport. Biochim Biophys Acta. 2002;1586:129-145.
75. Marzolini C, Tirona RG, Kim RB. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics. 2004;5:273-282.
76. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64:123-128.
77. Weiss J, Dormann SM, Martin-Facklam M, Kerpen O, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003;305:197-204.
78. Yasui-Furukori N, Kaneko S. Digitalis intoxication induced by paroxetine co-administration. Lancet. 2006;367:788.
79. Burnell JM, Kirby WM. Effectiveness of a new compound, benemid, in elevating serum penicillin concentrations. J Clin Invest 1951;30:697-700.
80. Jariyawat S, Sekine T, Takeda M, et al. The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999;290:672-677.
81. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 2001;31:469-497.
82. Parker RB, Yates CR, Soberman JE, Laizure SC. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy. 2003;23:979-987.
83. Aszalos A, Thompson K, Yin JJ, Ross DD. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-giycoprotein (Pgp). Anticancer Res. 1999;19:1053-1064.
84. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein- mediated secretion. J Clin Pharmacol. 2000;40:91-98.
85. Eneroth A, Astrom E, Hoogstraate J, et al. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci. 2001;12:205-214.
86. Frohlich M, Albermann N, Sauer A, Walter-Sack I, Haefeli WE, Weiss J. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol. 2004;68:2409-2416.
87. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000;68:231-237.
88. Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, Zhu HJ. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl). 2006;183:490-499.
89. Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci. 2006;27:543-554.
90. Koren G, Woodland C, Ito S. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Hum Toxicol. 1998;40:45-46.
91. Leabman MK, Huang CC, Kawamoto M, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002;12:395-405.
92. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther. 2003;73:41-50.
93. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41-57.